![]() ![]() The FDA awarded a grant to the National Academies of Sciences, Engineering and Medicine to support a scientific meeting on ADHD in adults and considerations for diagnosis and treatment. The agencies are asking manufacturers that do not wish to increase production to relinquish their remaining 2023 allotment so other manufacturers can increase production.Īdditionally, the FDA is asking health care providers to take a look at diagnosis and treatment of ADHD, including in adult patients. Data for 2023 show a similar trend, the letter said. However, officials said manufacturers did not produce the full amount permitted in 2022.Ī DEA analysis of inventory, manufacturing and sales data revealed only 70% of the allotted quota was sold in 2022, and approximately 1 billion more doses could have been produced. Therefore, the DEA sets limits on how much can be produced. Stimulants are controlled substances that have a high potential for abuse, which can lead to addiction and overdose. While the agencies cannot control how much medication is produced, leaders note that manufacturers are not producing as much as allowed. ![]() According to the Centers for Disease Control and Prevention, the percentages in certain groups increased by more than 10%, particularly during 2020-’21 when virtual prescribing was permitted because of the COVID-19 public health emergency. While the delay has been resolved, its effect coupled with additional factors such as record-high prescription rates of stimulant medication, continue to leave some without access.įrom 2012-’21, the dispensing of amphetamine products and other stimulants increased by 45.5% in the United States. “We are urging all stakeholders to work together to resolve these shortages as quickly as possible.”įactors contributing to the shortage include a manufacturing delay experienced by one drugmaker last fall. “This is not a problem that the FDA and DEA can solve on our own,” the letter states. Milgram, said the agencies are aware of the importance prescription stimulants play in treating ADHD, binge eating disorder and narcolepsy. Califf, M.D., and DEA Administrator Anne M. The letter, signed by FDA Commissioner Robert M. The Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) called on drug manufacturers Tuesday to increase production of stimulant prescription drugs to address shortages of medicine used to treat children with attention-deficit/hyperactivity disorder (ADHD) and other disorders. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |